Results 261 to 270 of about 1,245,695 (368)

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

HemaSphere, 2022
J. Senapati, J. Ishizawa, H. A. Abbas, S. Loghavi, G. Borthakur, G. C. Issa, S. I. Dara, R. Pourebrahim, N. Daver, E. J. Jabbour, S. M. Kornblau, N. Pemmaraju, G. Garcia-Manero, F. Ravandi, M. Muftuoglu, J. Khoury, C. DiNardo, M. Andreeff   +17 more
doaj   +1 more source

Remissions in leukemia of childhood following acute infectious disease. Staphylococcus and streptococcus, varicella, and feline panleukopenias [PDF]

, 1953
Howard R. Bierman, D. Michael Crile, Kenneth S. Dod, Keith H. Kelly, Nicholas I. Petrakis, Laurens P. White, Michael B. Shimkin   +6 more
openalex   +1 more source

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

Advanced Science, EarlyView.
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde   +3 more
wiley   +1 more source

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations

Haematologica, 2015
Sabine Jeromin, Torsten Haferlach, Sandra Weissmann, Manja Meggendorfer, Christiane Eder, Niroshan Nadarajah, Tamara Alpermann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger   +10 more
doaj   +1 more source

FOLIC ACID ANTAGONISTS IN THE TREATMENT OF ACUTE AND SUBACUTE LEUKEMIA [PDF]

, 1950
William Dameshek, Milton H. Freedman, LESTER A. STEINBERG   +2 more
openalex   +1 more source

SMC4 Promotes Prostate Cancer Cell Proliferation and Metastasis via the Rheb/mTOR Pathway

Advanced Science, EarlyView.
Structural maintenance of chromosome protein 4 (SMC4) has been implicated in prostate cancer metastasis. Knockdown of SMC4 in RM1‐LM cells significantly attenuates proliferation, migration, and lung metastasis in vivo. Furthermore, SMC4 interacts with GLUT1 (Slc2a1), thereby enhancing glycolysis, ATP production, and activation of the Rheb/mTOR pathway.
Wei Zhang, Siyuan Qin, Xiaokang Li, Ming Chang, Tianzi Wei, Xin Huang, Haibo Tong, Xia Guo, Yi Lu, Jian Zhang   +9 more
wiley   +1 more source

The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms

Haematologica, 2018
Manja Meggendorfer, Sabine Jeromin, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach   +4 more
doaj   +1 more source

P1590: OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES –A TERTIARY CANCER CENTER EXPERIENCE

HemaSphere, 2022
K. Kim, H. Ahaneku, M. Deborah, K. Sasaki, D. Hammond, K. Chien, J. Adachi, A. Ferrajoli   +7 more
doaj   +1 more source

Biological properties of the mouse leukemia agent [PDF]

, 1953
Ludwik Gross
openalex   +1 more source

The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2

Advanced Science, EarlyView.
Ovarian cancer‐derived extracellular vesicles (EVs) transfer INAVA mRNA to normal ovarian fibroblasts (NOFs). Translated INAVA protein inhibits HMGA2 phosphorylation‐dependent ubiquitylation and proteasomal degradation, promoting NOF activation.
Lingkai Gu, Zhangjin Shen, Shizhen Shen, Conghui Wang, Yuwan Liu, Xinyi Wei, Mengxia Zheng, Jiaxin Gu, Xiaojing Chen, Yi Sun, Junfen Xu, Yan Lu, Weiguo Lu   +12 more
wiley   +1 more source